Probatebeta
Target

CTLA4

Cytotoxic T-lymphocyte protein 4

As of the edition of 20 October 2026, CTLA4 (cytotoxic T-lymphocyte protein 4, UniProt P16410) has 15 drugs tested at it and 28 companies on the list, 5 on route A and 2 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P16410
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
22
Disease areas
Cancer; Skin and connective tissue; Digestive system; Urinary and reproductive; Pregnancy and women's health; Lungs and airways; Hormones; Blood and lymph
Registered trials of its drugs
1,343

Drugs at this target

StatusCount
Marketed2
Active8
Stopped3
Status not established2
Total15
DrugStatusFurthest phaseUS protection
IpilimumabMarketedPhase 4Ends 2027
TremelimumabMarketedPhase 3Ends 2034
CadonilimabActivePhase 3none listed
BotensilimabActivePhase 3none listed
ErfonrilimabActivePhase 3none listed
SHR-8068ActivePhase 3none listed
ZalifrelimabStoppedPhase 2none listed
IBI310ActivePhase 3none listed
QuavonlimabStatus not establishedPhase 3none listed
LorigerlimabActivePhase 2none listed
VudalimabStoppedPhase 2none listed
KD6001Status not establishedPhase 2none listed

12 of 15 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A5
Route B2
Engaged19
Undetermined2
Total on the list28
Three companies on route A or B, with the route only
CompanyRoute
Bristol Myers SquibbRoute B
AstraZenecaRoute B
Innovent BiologicsRoute A

The other 25 companies at CTLA4

In the product

28 companies in all; 25 are not named here, and no score is.

See the 28 companies at CTLA4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at CTLA4

Other targets in cancer